We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abiomed's (ABMD) Impella RP With SmartAssist Gets FDA Nod
Read MoreHide Full Article
Abiomed, Inc. recently received FDA pre-market approval (PMA) for its newest right heart pump — the Impella RP with SmartAssist. The FDA has deemed the new pump as safe and effective when it comes to treatment of right heart failure for up to 14 days.
It is worth mentioning that Impella RP with SmartAssist is an innovative advancement of Impella RP (granted a PMA by the FDA in 2017). Moreover, in last June, the FDA issued an emergency use authorization (EUA) for Impella RP for the purpose of treating patients suffering from COVID-19 associated right heart failure or decompensation, including pulmonary embolism (PE).
This announcement is likely to provide a substantial boost to Abiomed’s Impella product portfolio.
Impella RP With SmartAssist at a Glance
As the first dual-sensor technology heart pump, it offers real-time guidance and aids with pump management and weaning. In fact, the pump has been created for a simple setup and insertion. It has been improved with Impella Connect to help in remote monitoring from any internet-connected device through a secure, Health Insurance Portability and Accountability Act (HIPAA)-compliant website.
Image Source: Zacks Investment Research
Notably, SmartAssist technology is also available on Impella CP and Impella 5.5 with respect to management of left heart failure and early detection of right heart failure.
More on the News
According to physicians in the cardiology space, the addition of SmartAssist technology to Impella RP is an important step forward to help them in achieving improved patient outcomes with an enhanced design and intuitive metrics.
When it comes to improving patient survival rates, early identification of right heart failure along with early action is extremely important. Per data, Impella RP aids in improving survival rates greatly with respect to critically ill patients who require right heart hemodynamic support.
Market Prospects
Per a report by MarketsandMarkets, the global hemodynamic monitoring systems market is projected to reach $1.17 billion by 2023 from an estimated $857.8 million in 2018, witnessing a CAGR of 6.4%. Technological advancements in hemodynamic monitoring systems, growing research into these systems, increasing prevalence of cardiovascular diseases and diabetes are some of the factors driving this market’s growth.
Hence, this PMA from the FDA comes at an opportune time for Abiomed.
Recent Developments
This month, the company announced its buyout of preCARDIA to enhance treatment for patients with acute decompensated heart failure (“ADHF”). The acquisition of preCARDIA, a developer of a proprietary catheter and controller, is expected to complement Abiomed’s product portfolio for better patient outcomes.
In April, Abiomed announced the final results of the physician-led National Cardiogenic Shock Initiative (NCSI) Study. The results demonstrated a significant survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization.
Price Performance
Shares of the Zacks Rank #4 (Sell) company have gained 22.8% in the past year compared with the industry’s growth of 21.1%.
Veeva Systems’ long-term earnings growth rate is estimated at 15.8%.
DaVita’s long-term earnings growth rate is estimated at 14.4%.
Baxter International’s long-term earnings growth rate is projected at 9.3%.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
Image: Bigstock
Abiomed's (ABMD) Impella RP With SmartAssist Gets FDA Nod
Abiomed, Inc. recently received FDA pre-market approval (PMA) for its newest right heart pump — the Impella RP with SmartAssist. The FDA has deemed the new pump as safe and effective when it comes to treatment of right heart failure for up to 14 days.
It is worth mentioning that Impella RP with SmartAssist is an innovative advancement of Impella RP (granted a PMA by the FDA in 2017). Moreover, in last June, the FDA issued an emergency use authorization (EUA) for Impella RP for the purpose of treating patients suffering from COVID-19 associated right heart failure or decompensation, including pulmonary embolism (PE).
This announcement is likely to provide a substantial boost to Abiomed’s Impella product portfolio.
Impella RP With SmartAssist at a Glance
As the first dual-sensor technology heart pump, it offers real-time guidance and aids with pump management and weaning. In fact, the pump has been created for a simple setup and insertion. It has been improved with Impella Connect to help in remote monitoring from any internet-connected device through a secure, Health Insurance Portability and Accountability Act (HIPAA)-compliant website.
Notably, SmartAssist technology is also available on Impella CP and Impella 5.5 with respect to management of left heart failure and early detection of right heart failure.
More on the News
According to physicians in the cardiology space, the addition of SmartAssist technology to Impella RP is an important step forward to help them in achieving improved patient outcomes with an enhanced design and intuitive metrics.
When it comes to improving patient survival rates, early identification of right heart failure along with early action is extremely important. Per data, Impella RP aids in improving survival rates greatly with respect to critically ill patients who require right heart hemodynamic support.
Market Prospects
Per a report by MarketsandMarkets, the global hemodynamic monitoring systems market is projected to reach $1.17 billion by 2023 from an estimated $857.8 million in 2018, witnessing a CAGR of 6.4%. Technological advancements in hemodynamic monitoring systems, growing research into these systems, increasing prevalence of cardiovascular diseases and diabetes are some of the factors driving this market’s growth.
Hence, this PMA from the FDA comes at an opportune time for Abiomed.
Recent Developments
This month, the company announced its buyout of preCARDIA to enhance treatment for patients with acute decompensated heart failure (“ADHF”). The acquisition of preCARDIA, a developer of a proprietary catheter and controller, is expected to complement Abiomed’s product portfolio for better patient outcomes.
In April, Abiomed announced the final results of the physician-led National Cardiogenic Shock Initiative (NCSI) Study. The results demonstrated a significant survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization.
Price Performance
Shares of the Zacks Rank #4 (Sell) company have gained 22.8% in the past year compared with the industry’s growth of 21.1%.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Veeva Systems Inc. (VEEV - Free Report) , DaVita Inc. (DVA - Free Report) and Baxter International Inc. (BAX - Free Report) , each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Veeva Systems’ long-term earnings growth rate is estimated at 15.8%.
DaVita’s long-term earnings growth rate is estimated at 14.4%.
Baxter International’s long-term earnings growth rate is projected at 9.3%.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>